MeSH D009362 - neoplasm metastasis
Favorite
Competitive Landscape
Events Timeline
Commercial
Clinical Trials
Competitive landscape
D009362:Â
Neoplasm metastasis
D000079822:Extranodal extension
0 Companies
0 Drugs
Success rate
D008207:Lymphatic metastasis
0 Companies
0 Drugs
Success rate
D009360:Circulating neoplastic cells
0 Companies
0 Drugs
Success rate
D009366:Neoplasm seeding
0 Companies
0 Drugs
Success rate
D009382:Unknown primary neoplasms
0 Companies
0 Drugs
Success rate
D061206:Neoplasm micrometastasis
0 Companies
0 Drugs
Success rate
Events Timeline
Commercial
Company Name | Drug Name | Trade Name | Patent Expires | Approval Date | Revenue | Period |
|---|---|---|---|---|---|---|
| Teva | Ibandronic acid | Ibandronic Acid Teva |  | 2010-09-17 |  |  |
| Irinotecan | Irinotecan |  | 2008-02-27 |  |  | |
| Sandoz | Ibandronic acid | Ibandronic Acid Sandoz |  | 2011-07-26 |  |  |
| Irinotecan | Irinotecan |  | 2008-02-27 |  |  | |
| Amgen | Denosumab | Xgeva |  | 2011-07-13 | $2,137 M | Q2/23-Q1/24 |
| Atnahs Pharmaceuticals | Ibandronic acid | Bondronat |  | 1996-06-25 |  |  |
| Novast Laboratories | Irinotecan | Irinotecan |  | 2017-05-26 |  |  |
| Cipla | Irinotecan | Irinotecan |  | 2008-02-20 |  |  |
1
2
3
>
Clinical Trials
Historical Success Rate
Phase 1
77%79/103
Phase 2
37%49/133
Phase 3
19%16/84
Approved: 7Overall Success rate: 5%
All Clinical Trials
Therapeutic Areas:
All
Classification:
All
Approval:
All
Status:
All
Phases:
All
Company name | Phase 1 | Phase 2 | Phase 3 | Phase 4 | Drug Name |
|---|---|---|---|---|---|
1
2
>
© 2020-2023 Collaborative Drug Discovery Inc. (CDD) | Terms of Use